Story type: Industry

  • Melbourne innovation set to revolutionise cell therapy industry

    A world-leading Melbourne innovation is rapidly changing the way cell therapies are manufactured to treat diseases including stroke and cerebral palsy, taking these treatments out of the lab and into hospitals. The new cell-processing technology, ROTEA, developed by Melbourne start-up, Scinogy in conjunction with Hudson Institute of Medical Research, is significantly reducing the costs and…  Read more

    A Melbourne innovation is rapidly changing the way cell therapies are manufactured to treat diseases including stroke & cerebral palsy.
  • Hudson Institute enters into research alliance with Invion Limited

    Hudson Institute has entered into a Research and Development Alliance Agreement with Invion Limited to provide key scientific assessment of Invion’s cancer treatment technology, Photosoft. The collaboration will initially focus on the treatment of ovarian cancer, with a view to expanding research and development projects into other forms of cancer. Hudson Institute will provide the…  Read more

  • Childhood cancer ‘organoid’ program set to revolutionise treatment

    The Hudson Monash Precision Medicine Program hopes to significantly improve treatment for childhood cancer patients with the greatest unmet clinical need – those diagnosed with brain cancers and solid tumours. Launched today (February 7) ahead of International Childhood Cancer Day on February 15, the two year program is being established with a $1.3 million investment…  Read more

  • When science meets innovation: cell therapies

    Leading Australian stem cell researcher, Dr Rebecca Lim has just returned from Toronto, the global centre of cell therapies research and a hotbed of innovation and start-ups. She shares what happens when science meets innovation and commercialisation. You’ve just been to Toronto, Canada to visit the Centre for Commercialisation of Regenerative Medicine. What was the…  Read more

  • Next Big Idea Award winners announced

    Five innovative ‘Big Ideas’ were presented by PhD students and early career researchers (ECRs) from Hudson Institute on August 17 to a panel of expert judges from industry, research and business development, with prizes and mentoring for the best and runner-up ideas. Projects pitched included two new diagnostic tests – one for autoimmune disease and another for infectious…  Read more

  • Launch of the Gandel Genomics Centre to enable next generation health care

    The new Gandel Genomics Centre, launched at Hudson Institute of Medical Research today (June 19) by Mr Frank McGuire, Parliamentary Secretary for Medical Research, will play a vital role in transforming the future of Victorian healthcare. The Gandel Genomics Centre will utilise world-leading technology capabilities at the Monash Health Translation Precinct and new scientific expertise…  Read more

  • Dr Tracey Edgell awarded the 2017 Fielding Innovation Award

    The 2017 Fielding Innovation Award has been awarded to Dr Tracey Edgell, from the Centre for Reproductive Health, to further her research into stimulating factor CSF3 and its role in improving female fertility.…  Read more

    Dr Tracey Edgell from the Endometrial Infertility Research Group at Hudson Institute
  • Creating next generation medicines: new industry collaboration announced

    Hudson Institute of Medical Research and Monash University have announced a new research collaboration with the Swiss-based healthcare company Roche (F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.) The collaboration aims to develop next generation treatments for autoimmune diseases, focused on proteins targeting novel molecular pathways.…  Read more

  • Dr Rebecca Lim invited to present work at BIO SPARK, Stanford

    Dr Rebecca Lim has been invited to present her work with Business Development Director, Rob Merriel on amniotic exosomes at the prestigious Stanford University BIO SPARK Showcase in San Francisco on 17 October.…  Read more

    Associate Professor Rebecca Lim from the Amnion Cell Biology Research Group at Hudson Institute
  • Molecular analysis of paediatric brain cancer could become ‘gold standard’ for tailored treatment

    Researchers at Hudson Institute of Medical Research are working to establish and pilot an Australian-first service for analysing the most common type of paediatric solid brain cancer tumour, medulloblastoma, to enable more effective treatment for these paediatric brain cancer patients.…  Read more